Le Lézard
Classified in: Health, Business
Subject: CXP

Catalent Expands Beauty and Plant-Based Consumer Health Softgel Capabilities at its Facilities in Canada and Brazil


SOMERSET, N.J., June 30, 2020 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.

The expansion projects include new softgel encapsulation lines at each site, dedicated to Catalent's proprietary Vegicaps® plant-based capsule and CosmoPod® twist-off capsule technologies. The increased capacity will enable Catalent to support its customers in both North and Latin America to develop products for consumers seeking all-natural and plant-based vitamins, minerals and supplements, using its Vegicaps capsule; and those looking for innovative, easy-to-use, unit-dose beauty care products, through its CosmoPod technology.

"We have seen increased consumer demand for greater product choice, with sales of plant-based softgel technologies growing by more than 25% globally in recent years. Additionally, Brazil has grown to become the world's fourth-largest market for beauty care products," commented Dr. Aris Gennadios, President, Softgel & Oral Technologies, Catalent. "While we have been supplying the North and Latin American markets with plant-based softgel capsules from our manufacturing sites in Italy and Germany, this investment allows us to provide local supply solutions to markets that complement existing capabilities in Europe."

Catalent's 110,000 square-foot facility in Strathroy, Ontario, and its 124,600 square-foot facility in Sorocaba, Brazil, both offer a broad range of integrated formulation, manufacturing, and packaging services to provide full-service turnkey solutions for the pharmaceutical, consumer health, and beauty industries.

For more information about Catalent's Consumer Health capabilities, please visit https://consumerhealth.catalent.com

About Catalent Consumer Health & Beauty
Catalent brings over 85 years of experience and expertise in softgel, fast-dissolve, and oral solid dose formulation development and supply of over-the-counter, nutritional supplement and beauty products to market. With consumer-preferred dose forms and advanced development and commercial manufacturing expertise, Catalent helps differentiate and grow brands, to get better products to market faster. Catalent partners with 23 of the top 25 consumer health companies and produces more than 5,000 consumer health and beauty products, which are marketed in more than 70 countries. For more information, visit consumerhealth.catalent.com

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.tm

 

SOURCE Catalent


These press releases may also interest you

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...



News published on and distributed by: